Results 211 to 220 of about 10,843 (242)
Some of the next articles are maybe not open access.
Research Journal of Pharmacy and Technology, 2023
Oxidative stress in β-TM (beta-thalassemia major) patients is associated with increased of malondialdehyde (MDA) level and also decreased of superoxide dismutase (SOD) level. Deferiprone and deferasirox, which are used for the treatment of iron overload,
Andreas Budi Wijaya +5 more
semanticscholar +1 more source
Oxidative stress in β-TM (beta-thalassemia major) patients is associated with increased of malondialdehyde (MDA) level and also decreased of superoxide dismutase (SOD) level. Deferiprone and deferasirox, which are used for the treatment of iron overload,
Andreas Budi Wijaya +5 more
semanticscholar +1 more source
Research Journal of Pharmacy and Technology, 2023
Purpose: This study aims to develop and validate a RP-HPLC method for simultaneous estimation of deferiprone and its synthesized impurity. Method: Structure of impurity was confirmed by spectral analysis while their purity was confirmed by HPLC analysis.
S. Sutar +5 more
semanticscholar +1 more source
Purpose: This study aims to develop and validate a RP-HPLC method for simultaneous estimation of deferiprone and its synthesized impurity. Method: Structure of impurity was confirmed by spectral analysis while their purity was confirmed by HPLC analysis.
S. Sutar +5 more
semanticscholar +1 more source
Annals of the New York Academy of Sciences, 2010
Deferiprone (DFP) has been evaluated in a wide range of disorders, but most data come from transfusion‐dependent thalassemia. The safety and tolerability profile includes gastrointestinal complaints, liver enzymes elevation, weight gain, arthropathy, neutropenia, and agranulocytosis.
PIGA, Antonio Giulio +5 more
openaire +2 more sources
Deferiprone (DFP) has been evaluated in a wide range of disorders, but most data come from transfusion‐dependent thalassemia. The safety and tolerability profile includes gastrointestinal complaints, liver enzymes elevation, weight gain, arthropathy, neutropenia, and agranulocytosis.
PIGA, Antonio Giulio +5 more
openaire +2 more sources
Annals of the New York Academy of Sciences, 2005
Abstract: Recent results from independent studies suggest that deferiprone is more cardioprotective than deferoxamine. Patients on long‐term treatment with deferiprone have a better myocardial magnetic resonance imaging pattern and less chance to develop a new cardiac disease or worsen an existing one.
PIGA, Antonio Giulio +5 more
openaire +3 more sources
Abstract: Recent results from independent studies suggest that deferiprone is more cardioprotective than deferoxamine. Patients on long‐term treatment with deferiprone have a better myocardial magnetic resonance imaging pattern and less chance to develop a new cardiac disease or worsen an existing one.
PIGA, Antonio Giulio +5 more
openaire +3 more sources
Deferiprone, efficacy and safety
The Indian Journal of Pediatrics, 2004Deferiprone (L1), the new oral iron chelator has been studied in several countries for its efficacy and toxicity with some conflicting observations. Toxicity involving joints has been reported more frequently in Indian patients. The authors planned to include larger number of Indian thalassemics in studying safety and efficacy of Deferiprone.Seventy ...
H. P. Pati +5 more
openaire +3 more sources
Deferiprone‐associated myelotoxicity
European Journal of Haematology, 1994Abstract: Agranulocytosis developed in a 63‐year‐old patient with myelodysplasia 6 weeks after commencing treatment with the oral iron chelator deferiprone (L1, 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one, CP20) at a daily dose of 79 mg/kg. This was the 3rd case of agranulocytosis (neutrophils 0 times 109/***1) in clinical trials of L1 at the Royal Free ...
Beatrix Wonke +2 more
openaire +3 more sources
Deferiprone and hepatic fibrosis
Blood, 2003We write to request that Wanless and colleagues correct the record on the efficacy and safety of deferiprone for treatment of transfusional iron overload by providing the data on hepatic iron omitted from their publication in Blood.
Gary M. Brittenham +6 more
openaire +3 more sources
The Role of Deferiprone in Iron Chelation
New England Journal of Medicine, 2018Iron Chelation Iron overload can compromise the cardiac, hepatic, renal, and endocrine systems. Orally active iron chelators increase iron excretion, and in some instances, the combination of oral ...
Robert C. Hider, A. Victor Hoffbrand
openaire +2 more sources
ORAL IRON CHELATION WITH DEFERIPRONE
Pediatric Clinics of North America, 1997Deferiprone is the most widely studied oral iron chelator and, at present, the only one shown to be effective in achieving negative iron balance in long-term clinical trials for chronic iron overload. Because of its adverse effects (e.g., agranulocytosis and arthropathy) its use is presently restricted to clinical trials and to countries where ...
Orna Diav-Citrin, Gideon Koren
openaire +3 more sources
Pharmacogenomics of Deferiprone Metabolism.
Blood, 2005Abstract Individuals with transfusion-dependent β-thalassemia can be affected by iron accumulation in the heart and liver, resulting in liver fibrosis, cardiomyopathy and eventual death. As a result, iron chelation treatment is a necessary concurrent therapy for many patients.
Eden Haverfield +4 more
openaire +2 more sources